

About Idylla™

Biocartis' fully automated, real-time PCR-based molecular system offers fast and easy access to high-quality biomarker data.

- Speed
Sample to result in 35 to 150 minutes
- Multiplexing capability
Can detect up to 30 molecular targets in standard mode⁷
- Outstanding ease of use
Less than 2 minutes hands-on-time
- Access on-demand
Run samples on demand, no need for batching
- Scalable
Connect up to 8 instruments per console
- Idylla™ Connect
LIS and remote connectivity capability





Biocartis NV
 Generaal De Wittelaan 11 B3 -2800 Mechelen - Belgium
 T +32 15 632 888

customerservice@biocartis.com - www.biocartis.com

- 1 Formalin-fixed paraffin-embedded
- 2 Jean-Yves Douillard, M.D., Ph.D., Kelly S. Oliner, Ph.D., Salvatore Siena, M.D., et al. Panitumumab-FOLFFOX4 Treatment and RAS Mutations in Colorectal Cancer. N Engl J Med 2013;369:1023-34.
- 3 The Idylla™ KRAS Mutation Assay contains PlexZyme™ and PlexPrime™ technology covered by patents granted and pending in certain jurisdictions, which are supplied under license of SpeedX Pty Ltd. PlexZyme™ and PlexPrime™ are trademarks of SpeedX Pty Ltd.
- 4 Hammond SP, Gagne LS, Stock SR, Marty FM, Gelman RS, Marasco WA, Poritz MA, Baden LR. 2012. Respiratory virus detection in immunocompromised patients with FilmArray respiratory panel compared to conventional methods. J Clin Microbiol. 50:3216-3221.
- 5 Jennings LC, Anderson TP, Werno AM, Beynon KA, Murdoch DR. 2004. Viral etiology of acute respiratory tract infections in children presenting to hospital: role of polymerase chain reaction and demonstration of multiple infections. Pediatr Infect Dis J 23:1003-1007.
- 6 Landry ML. 2011. Diagnostic tests for influenza infection. Curr. Opin. Pediatr. 23:91-97. doi:10.1097/MOP.0b013e328341ebd9.
- 7 Specific test protocols are under development to enable the detection of more than 30 biomarkers per sample. Idylla™ KRAS Mutation test detects 21 mutations within the KRAS gene.

Idylla™, Idylla™ KRAS Mutation Test and Idylla™ BRAF Mutation Test are CE-marked IVDs. Biocartis' trademark and logo are registered in Europe.

The MGB Probe contained in the Idylla™ BRAF Mutation Test is covered by one or more of the following US patents and corresponding patents outside the US: 5,801,155 and 6,084,102 and is sold under a license from the ELITech Group.



Simple, rapid, highly sensitive diagnostics at hand

BRAF **KRAS** **IFV - RSV**



Less than 2 minutes hands-on time
 90 minutes total turnaround time
 Directly from FFPE tissue sections

Less than 1 minute hands-on time
 50 minutes turnaround time
 Samples can be derived directly from nasal swab or nasopharyngeal swab in universal transport media (UTM)

BRAF

About 50 percent of all melanomas harbor mutations in the **BRAF** oncogene. Idylla™, Biocartis' fully automated, real-time PCR, offers fast and easy access to high-quality biomarker data. **Idylla™ BRAF Mutation Test** allows detection of BRAF mutations directly from FFPE¹ tissue sections in 90 minutes with less than 2 minutes hands-on time. A game-changing technology when time matters most.

KRAS

About 45% of all metastatic colorectal tumors harbor mutations in exons 2, 3 and 4 of the **KRAS** oncogene². Idylla™, Biocartis' fully automated, real-time PCR, offers fast and easy access to high quality biomarker data. The Idylla™ KRAS Mutation Test allows detection of KRAS mutations directly from (FFPE) tissue sections in approx. 2 hours with less than 2 minutes hands-on time. The **Idylla™ KRAS Mutation Test** is capable of detecting 21 relevant KRAS mutations: 7 mutations in codons 12 and 13 (exon 2), 9 mutations in codons 59 and 61 (exon 3) and 5 mutations in codons 117 and 146 (exon 4). The game-changing real-time PCR based technology uses a unique combination of PlexPrime™ and PlexZyme™, which allows high sensitivity and specificity combined with high multiplexing capability³.

Less than 2 minutes hands-on time
 Approx. 120 minutes total turnaround time
 Directly from FFPE tissue sections



IFV - RSV

DEVELOPED BY
 JANSSEN DIAGNOSTICS BVBA

Respiratory tract infections (RTI) cause thousands of deaths per year and have an enormous socioeconomic impact. Their etiology is often unknown as infections often present with similar symptoms⁴, and several different viruses may be in circulation simultaneously at any given time⁵. Timely detection and discrimination of the infecting pathogens is crucial to optimize treatment, to prevent unnecessary antibiotic use, and to prevent secondary spread of infection⁶. The **Idylla™ Respiratory IFV-RSV panel**, currently in late-stage development, is a molecular assay that identifies these viruses with world class sensitivity in as quickly as 50 minutes, and requires less than 1 minute hands-on time.


* For Research Use Only. Not for use in diagnostic procedures.



“Excellent sensitivity, very quick results and very little hands-on time.”

Dr. Bellosillo Head Molecular lab, Hospital del Mar

BRAF KRAS



① Scan sample and cartridge



② Load sample into the cartridge



③ Insert the cartridge into the Idylla™ system


IFV - RSV



① Scan sample and cartridge



② Insert swab in the cartridge



③ Insert the cartridge in the Idylla™ system